CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion

BACKGROUND: Cisplatin is more often used to treat ovarian cancer (OvCa), which provides modest survival advantage primarily due to chemo-resistance and up regulated anti-apoptotic machineries in OvCa cells. Therefore, targeting the mechanisms responsible for cisplatin resistance in OvCa cell may imp...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Johnson, Erica L, Singh, Rajesh, Johnson-Holiday, Crystal M, Grizzle, William E, Partridge, Edward E, Lillard, James W, Singh, Shailesh
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2010
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2914045/
https://ncbi.nlm.nih.gov/pubmed/20565782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1757-2215-3-15
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars